Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-Ku, Tokyo 113-8677, Japan.
Vaccine. 2011 Aug 5;29(34):5694-8. doi: 10.1016/j.vaccine.2011.06.003. Epub 2011 Jun 29.
We evaluated the immunogenicity and safety of the influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. A total of 182 HIV-infected and 42 HIV-uninfected subjects were enrolled, and antibody (ab) titers were measured by hemagglutination-inhibition assay at baseline and 32.3±10.4 and 29.7±3.3 days after vaccination, respectively. In the HIV-infected cohort, ab titers ≥ 1:40 at baseline and post-vaccination were 12.6% and 49.5%, respectively. The seroconversion rate, defined as either an ab titer ≤ 1:10 before and ≥ 1:40 after or ≥ 1:10 before and ≥ 4-fold increase in ab titer, was only 38.5% in the HIV-infected cohort, whereas the rate was 85.7% in the HIV-uninfected cohort. Multivariate logistic regression analysis showed that the CD4 cell count was the only significant predictor of a positive vaccine response. There were no serious adverse events in any of the subjects receiving the vaccine. Additional study is warranted to identify a more effective method of vaccinating HIV-infected Japanese subjects.
我们评估了甲型 H1N1 流感 2009 单价疫苗在日本 HIV 感染者中的免疫原性和安全性。共纳入 182 例 HIV 感染者和 42 例 HIV 未感染者，分别在基线和接种后 32.3±10.4 天和 29.7±3.3 天通过血凝抑制试验测量抗体（ab）滴度。在 HIV 感染者队列中，基线和接种后的 ab 滴度≥1:40 者分别为 12.6%和 49.5%。血清转化率定义为接种前 ab 滴度≤1:10 和接种后≥1:40，或接种前 ab 滴度≥1:10 和滴度增加≥4 倍，在 HIV 感染者队列中仅为 38.5%，而在 HIV 未感染者队列中为 85.7%。多变量逻辑回归分析显示，CD4 细胞计数是疫苗应答阳性的唯一显著预测因素。接受疫苗接种的受试者均无严重不良事件。有必要进一步研究以确定更有效的方法来为日本 HIV 感染者接种疫苗。
